EP4090684A4 - Anticorps anti-nkp30 et méthode d'utilisation - Google Patents

Anticorps anti-nkp30 et méthode d'utilisation Download PDF

Info

Publication number
EP4090684A4
EP4090684A4 EP21741171.9A EP21741171A EP4090684A4 EP 4090684 A4 EP4090684 A4 EP 4090684A4 EP 21741171 A EP21741171 A EP 21741171A EP 4090684 A4 EP4090684 A4 EP 4090684A4
Authority
EP
European Patent Office
Prior art keywords
methods
nkp30 antibodies
nkp30
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21741171.9A
Other languages
German (de)
English (en)
Other versions
EP4090684A1 (fr
Inventor
Tong Zhang
Liu XUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beigene Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of EP4090684A1 publication Critical patent/EP4090684A1/fr
Publication of EP4090684A4 publication Critical patent/EP4090684A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21741171.9A 2020-01-17 2021-01-15 Anticorps anti-nkp30 et méthode d'utilisation Pending EP4090684A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020072733 2020-01-17
PCT/CN2021/072191 WO2021143858A1 (fr) 2020-01-17 2021-01-15 Anticorps anti-nkp30 et méthode d'utilisation

Publications (2)

Publication Number Publication Date
EP4090684A1 EP4090684A1 (fr) 2022-11-23
EP4090684A4 true EP4090684A4 (fr) 2024-01-31

Family

ID=76863642

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21741171.9A Pending EP4090684A4 (fr) 2020-01-17 2021-01-15 Anticorps anti-nkp30 et méthode d'utilisation

Country Status (11)

Country Link
EP (1) EP4090684A4 (fr)
JP (1) JP2023510211A (fr)
KR (1) KR20220151164A (fr)
CN (1) CN115397854A (fr)
AU (1) AU2021207165A1 (fr)
BR (1) BR112022013977A2 (fr)
CA (1) CA3164182A1 (fr)
IL (1) IL294714A (fr)
MX (1) MX2022008745A (fr)
TW (1) TW202140556A (fr)
WO (1) WO2021143858A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056392A1 (fr) * 2002-12-23 2004-07-08 Innate Pharma Compositions pharmaceutiques presentant un effet sur la proliferation de cellules nk et procede utilisant ces compositions
WO2019226617A1 (fr) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971794C (fr) * 2007-10-04 2020-03-24 Zymogenetics, Inc. Zb7h6 membre de la famille b7 et compositions et procedes apparentes
EP2510011B2 (fr) * 2009-12-09 2021-03-31 Institut National de la Santé et de la Recherche Médicale Anticorps monoclonaux qui se lient à b7h6 et leurs utilisations
CN101985476B (zh) * 2010-10-29 2012-11-21 中国科学技术大学 抗人NKp30单克隆抗体的制备、鉴定及应用
WO2013033626A2 (fr) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Produits thérapeutiques ciblant un récepteur nkp30
EP3402494B1 (fr) * 2016-01-11 2021-04-07 The Board of Trustees of the Leland Stanford Junior University Protéines chimériques et procédés d'immunothérapie
CA3056227A1 (fr) * 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions et procedes d'elimination et de remplacement selectifs de cellules souches hematopoietiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056392A1 (fr) * 2002-12-23 2004-07-08 Innate Pharma Compositions pharmaceutiques presentant un effet sur la proliferation de cellules nk et procede utilisant ces compositions
WO2019226617A1 (fr) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021143858A1 *

Also Published As

Publication number Publication date
TW202140556A (zh) 2021-11-01
IL294714A (en) 2022-09-01
WO2021143858A1 (fr) 2021-07-22
EP4090684A1 (fr) 2022-11-23
KR20220151164A (ko) 2022-11-14
JP2023510211A (ja) 2023-03-13
CN115397854A (zh) 2022-11-25
AU2021207165A1 (en) 2022-07-21
MX2022008745A (es) 2022-07-27
CA3164182A1 (fr) 2021-07-22
BR112022013977A2 (pt) 2023-03-14

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
EP4031177A4 (fr) Anticorps anti-tnfr2 et méthodes d'utilisation
SG11202110145SA (en) Antibodies against sars-cov-2 and methods of using the same
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP4001305A4 (fr) Anticorps anti-tau et son utilisation
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
EP3930756A4 (fr) Anticorps se liant à lilrb4 et ses méthodes d'utilisation
EP3966248A4 (fr) Anticorps humanisés dirigés contre la mucine-16 et leurs procédés d'utilisation
EP4061848A4 (fr) Anticorps anti-ror-2 et méthodes d'utilisation
EP3983447A4 (fr) Anticorps contre muc1 et leurs méthodes d'utilisation
EP3870613A4 (fr) Anticorps alk2 et procédés d'utilisation associés
EP3740509A4 (fr) Anticorps anti-pd-l1 et méthodes d'utilisation
EP3746484A4 (fr) Anticorps anti-ms4a6a et leurs procédés d'utilisation
EP4007605A4 (fr) Anticorps anti-fcrn et leurs procédés d'utilisation
EP4061852A4 (fr) Anticorps dirigés contre tie-2 et méthodes d'utilisation
EP3994174A4 (fr) Anticorps anti-fzd monospecifiques et méthodes d'utilisation
AU2021352981A9 (en) Anti-cd94 antibodies and methods of use thereof
EP3947452A4 (fr) Anticorps anti-récepteur nmda et procédés d'utilisation
EP4061847A4 (fr) Anticorps monoclonal anti-b7-h3 et ses procédés d'utilisation
EP3972644A4 (fr) Anticorps mmp-9 et leurs procédés d'utilisation
EP3946453A4 (fr) Anticorps anti-axl et leurs méthodes d'utilisation
EP3880714A4 (fr) Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation
IL308260A (en) Antibodies against Tigit and methods of using them
EP3768298A4 (fr) Anticorps anti-pd-l2 humains et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240105

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/532 20060101ALI20231222BHEP

Ipc: G01N 15/14 20060101ALI20231222BHEP

Ipc: C07K 16/30 20060101ALI20231222BHEP

Ipc: G01N 33/577 20060101ALI20231222BHEP

Ipc: G01N 15/10 20060101ALI20231222BHEP

Ipc: C12R 1/91 20060101ALI20231222BHEP

Ipc: C12N 5/20 20060101ALI20231222BHEP

Ipc: C07K 16/28 20060101AFI20231222BHEP